RAZADYNE ER
LOE ApproachingNDAORALCAPSULE, EXTENDED RELEASE
Approved
Apr 2005
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 8h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RAZADYNE ER is an extended-release oral capsule approved in 2005 as a small-molecule therapeutic. The generic name and indication are not disclosed in available data, but the product is positioned as an oral capsule formulation.
LOE Approaching
As loss of exclusivity approaches, commercial teams should expect declining market share and team restructuring; career growth may be limited on legacy products.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
RAZADYNE ER offers limited career growth prospects given its approaching loss of exclusivity and minimal linked job openings (0 positions identified). Professionals assigned to this product should expect a defensive commercial strategy focused on market maintenance rather than expansion.
Brand ManagerField Sales Representative
Worked on RAZADYNE ER at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.